GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer

Andras Csejtei, Antax Tibold, Zsuzsa Varga, Katalin Koltai, Agoston Ember, Zsuzsa Orsos, G. Fehér, O. Horvath, I. Ember, Istvan Kiss

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Cancer of the colorectal region is the second most frequent cause of death among malignant diseases. The influence of two allelic polymorphisms of GSTM1 and GSTT1, and that of p53 gene codon 72 on colon cancer was investigated. Patients and Methods: Intraoperatively removed tissue samples were processed from colorectal cancer patients. Cancer-free human samples were used as matched controls. Samples were digested with proteinase-K. DNA solution was used for PCR amplification. Results: No significant difference was found between tumor patients and controls in the investigated polymorphisms. A significant association was found in Dukes' B stage patients between the GSTM1 and p53 gene variants and survival. In patients with GSTM1 null genotype and p53 ArglPro heterozygotes or Pro/Pro homozygotes the chance of survival is significantly lower than in the case of GSTM1 + and p53 Arg/Arg variants (p=0.009 and p=0.008, respectively). Conclusion: The significance of the investigated polymorphisms in prognosis is dependent on the tumor stage. These parameters might be used in certain cases as prognostic biomarkers in clinical diagnostics and in the planning of individual therapy.

Original languageEnglish
Pages (from-to)1917-1922
Number of pages6
JournalAnticancer Research
Volume28
Issue number3 B
Publication statusPublished - May 2008

Fingerprint

Colorectal Neoplasms
p53 Genes
Endopeptidase K
Neoplasms
Survival
Homozygote
Heterozygote
Codon
Colonic Neoplasms
Cause of Death
Biomarkers
Genotype
Polymerase Chain Reaction
DNA
Therapeutics

Keywords

  • Colorectal cancer
  • Dukes' stage
  • GSTM1
  • GSTT1
  • p53
  • Polymorphism
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Csejtei, A., Tibold, A., Varga, Z., Koltai, K., Ember, A., Orsos, Z., ... Kiss, I. (2008). GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer Research, 28(3 B), 1917-1922.

GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. / Csejtei, Andras; Tibold, Antax; Varga, Zsuzsa; Koltai, Katalin; Ember, Agoston; Orsos, Zsuzsa; Fehér, G.; Horvath, O.; Ember, I.; Kiss, Istvan.

In: Anticancer Research, Vol. 28, No. 3 B, 05.2008, p. 1917-1922.

Research output: Contribution to journalArticle

Csejtei, A, Tibold, A, Varga, Z, Koltai, K, Ember, A, Orsos, Z, Fehér, G, Horvath, O, Ember, I & Kiss, I 2008, 'GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer', Anticancer Research, vol. 28, no. 3 B, pp. 1917-1922.
Csejtei A, Tibold A, Varga Z, Koltai K, Ember A, Orsos Z et al. GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer Research. 2008 May;28(3 B):1917-1922.
Csejtei, Andras ; Tibold, Antax ; Varga, Zsuzsa ; Koltai, Katalin ; Ember, Agoston ; Orsos, Zsuzsa ; Fehér, G. ; Horvath, O. ; Ember, I. ; Kiss, Istvan. / GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. In: Anticancer Research. 2008 ; Vol. 28, No. 3 B. pp. 1917-1922.
@article{e259ae8875cc4c3fb9a7c3e9dc4daf81,
title = "GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer",
abstract = "Background: Cancer of the colorectal region is the second most frequent cause of death among malignant diseases. The influence of two allelic polymorphisms of GSTM1 and GSTT1, and that of p53 gene codon 72 on colon cancer was investigated. Patients and Methods: Intraoperatively removed tissue samples were processed from colorectal cancer patients. Cancer-free human samples were used as matched controls. Samples were digested with proteinase-K. DNA solution was used for PCR amplification. Results: No significant difference was found between tumor patients and controls in the investigated polymorphisms. A significant association was found in Dukes' B stage patients between the GSTM1 and p53 gene variants and survival. In patients with GSTM1 null genotype and p53 ArglPro heterozygotes or Pro/Pro homozygotes the chance of survival is significantly lower than in the case of GSTM1 + and p53 Arg/Arg variants (p=0.009 and p=0.008, respectively). Conclusion: The significance of the investigated polymorphisms in prognosis is dependent on the tumor stage. These parameters might be used in certain cases as prognostic biomarkers in clinical diagnostics and in the planning of individual therapy.",
keywords = "Colorectal cancer, Dukes' stage, GSTM1, GSTT1, p53, Polymorphism, Survival",
author = "Andras Csejtei and Antax Tibold and Zsuzsa Varga and Katalin Koltai and Agoston Ember and Zsuzsa Orsos and G. Feh{\'e}r and O. Horvath and I. Ember and Istvan Kiss",
year = "2008",
month = "5",
language = "English",
volume = "28",
pages = "1917--1922",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 B",

}

TY - JOUR

T1 - GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer

AU - Csejtei, Andras

AU - Tibold, Antax

AU - Varga, Zsuzsa

AU - Koltai, Katalin

AU - Ember, Agoston

AU - Orsos, Zsuzsa

AU - Fehér, G.

AU - Horvath, O.

AU - Ember, I.

AU - Kiss, Istvan

PY - 2008/5

Y1 - 2008/5

N2 - Background: Cancer of the colorectal region is the second most frequent cause of death among malignant diseases. The influence of two allelic polymorphisms of GSTM1 and GSTT1, and that of p53 gene codon 72 on colon cancer was investigated. Patients and Methods: Intraoperatively removed tissue samples were processed from colorectal cancer patients. Cancer-free human samples were used as matched controls. Samples were digested with proteinase-K. DNA solution was used for PCR amplification. Results: No significant difference was found between tumor patients and controls in the investigated polymorphisms. A significant association was found in Dukes' B stage patients between the GSTM1 and p53 gene variants and survival. In patients with GSTM1 null genotype and p53 ArglPro heterozygotes or Pro/Pro homozygotes the chance of survival is significantly lower than in the case of GSTM1 + and p53 Arg/Arg variants (p=0.009 and p=0.008, respectively). Conclusion: The significance of the investigated polymorphisms in prognosis is dependent on the tumor stage. These parameters might be used in certain cases as prognostic biomarkers in clinical diagnostics and in the planning of individual therapy.

AB - Background: Cancer of the colorectal region is the second most frequent cause of death among malignant diseases. The influence of two allelic polymorphisms of GSTM1 and GSTT1, and that of p53 gene codon 72 on colon cancer was investigated. Patients and Methods: Intraoperatively removed tissue samples were processed from colorectal cancer patients. Cancer-free human samples were used as matched controls. Samples were digested with proteinase-K. DNA solution was used for PCR amplification. Results: No significant difference was found between tumor patients and controls in the investigated polymorphisms. A significant association was found in Dukes' B stage patients between the GSTM1 and p53 gene variants and survival. In patients with GSTM1 null genotype and p53 ArglPro heterozygotes or Pro/Pro homozygotes the chance of survival is significantly lower than in the case of GSTM1 + and p53 Arg/Arg variants (p=0.009 and p=0.008, respectively). Conclusion: The significance of the investigated polymorphisms in prognosis is dependent on the tumor stage. These parameters might be used in certain cases as prognostic biomarkers in clinical diagnostics and in the planning of individual therapy.

KW - Colorectal cancer

KW - Dukes' stage

KW - GSTM1

KW - GSTT1

KW - p53

KW - Polymorphism

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=45949112212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45949112212&partnerID=8YFLogxK

M3 - Article

C2 - 18630481

AN - SCOPUS:45949112212

VL - 28

SP - 1917

EP - 1922

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 B

ER -